This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.
|Articles|July 28, 2022
The Building Blocks of Decentralized Clinical Trials
Author(s)Medable
A recent study by Morning Consult finds that >54% of US adults would be willing to participate in a clinical trial if it had a 30-minute-or-less commute. This is quite striking, given that <4% of the 328 million people in America are actively participating in clinical research today. The solution? - An accessible, intuitive digital clinical platform that connects sponsors, sites & patients, and replaces burdensome paper forms and physical visits with electronic consents (eConsent), electronic Clinical Outcome Assessments (eCOA’s), and remote visits (TeleVisits). Find out how Medable, the recognized industry leaders in Decentralized Clinical trials, can partner with your organization to digitally transform your clinical protocols. Your research teams can experience benefits such as; improved patient experience, higher quality outcomes data, & savings of US$25,000,000+ for individual studies. Download the White Paper now to learn how.
Related to this article
FDA approves Sun Pharma’s Ilumya for active psoriatic arthritis, BioMarin licenses a subcutaneous Fabry enzyme replacement therapy from GC Biopharma and Hanmi, and Lonza expands bioconjugation capacity in Visp to meet rising ADC demand.
In the second part of an interview for BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall shares 18-month stability data for a 414 mg/mL trastuzumab suspension and explains how ultra-high-concentration formulations could shorten administration and support at-home injection.
Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
The first-in-class molecule, licensed to Dianthus as DNTH212 outside Greater China, is designed to block type 1 interferon production and BAFF/APRIL-driven B-cell activity with a single drug.
HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.
The IL-23p19 inhibitor tildrakizumab becomes the third drug in its class approved for psoriatic arthritis, and the only one given exclusively by a healthcare provider.
Trending on BioPharm International
1
Iovance’s Lifileucel Reaches 52% Response Rate in Biomarker-Selected Lung Cancer Subgroup
2
Genmab’s Petosemtamab Plus Pembrolizumab Cuts Risk of Death by 50% in Phase 3 Head and Neck Cancer Trial
3
The BioPharm Brief: A Psoriatic Arthritis Approval, a Subcutaneous Fabry Bet, and ADC Capacity
4
Drug Digest: Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma
5